{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:37:28Z","timestamp":1777297048294,"version":"3.51.4"},"reference-count":7,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160129"],"award-info":[{"award-number":["82160129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473266"],"award-info":[{"award-number":["82473266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Talents Project of Gansu Province","award":["2019RCXM020"],"award-info":[{"award-number":["2019RCXM020"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2023-ZD-01"],"award-info":[{"award-number":["CY2023-ZD-01"]}]},{"name":"Major scientific research project for scientific and technological innovation in the health industry of Gansu Province","award":["GSWSZD-2024-17"],"award-info":[{"award-number":["GSWSZD-2024-17"]}]},{"name":"General Project of Gansu Province Joint Research Fund","award":["24JRRA929"],"award-info":[{"award-number":["24JRRA929"]}]},{"name":"Science and Technology Project of Chengguan District of Lanzhou City","award":["2020JSCX0073"],"award-info":[{"award-number":["2020JSCX0073"]}]},{"name":"Science and Technology Project of Chengguan District of Lanzhou City","award":["2020SHFZ0039"],"award-info":[{"award-number":["2020SHFZ0039"]}]},{"name":"Key Project of Science and Technology in Gansu province","award":["22ZD6FA054"],"award-info":[{"award-number":["22ZD6FA054"]}]},{"name":"Medical Research Innovation Ability Improvement Project of Lanzhou University","award":["lzuyxcx-2022-160"],"award-info":[{"award-number":["lzuyxcx-2022-160"]}]},{"name":"Excellent Textbook Cultivation Project of Lanzhou University","award":["lzuyxcx-2022-45"],"award-info":[{"award-number":["lzuyxcx-2022-45"]}]},{"name":"the Start-up Fund of Shanghai General Hospital","award":["02.06.01.24.201"],"award-info":[{"award-number":["02.06.01.24.201"]}]},{"name":"Key Projects of Digital Health under the Industry-University-Research Innovation Fund of Chinese Universities","award":["2024GY032"],"award-info":[{"award-number":["2024GY032"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Despite the establishment of combined local and systemic therapy as the standard approach for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), its efficacy remains constrained by two primary challenges: the immunosuppressive tumor microenvironment (TME) and treatment resistance. Recent research shows that factor Xa (FXa) boosts programmed death-ligand 1 (PD-L1) expression in tumor cells via the proteinase-activated receptor-2 (PAR-2) and signal transducer and activator of transcription 2 (STAT2) pathways, aiding immune evasion. Rivaroxaban, an FXa inhibitor, prevents portal vein thrombosis and disrupts the FXa\/PAR-2\/PD-L1 axis, restoring T cell function. Based on this mechanism, we propose that incorporating rivaroxaban as a core adjuvant into a long-term, \u2018local-targeted-immune\u2019 multimodal strategy can spatiotemporally reprogram the TME in advanced HCC with PVTT. This approach has the potential to effectively overcome treatment resistance and achieve sustained disease control. The hypothesis is readily testable in clinical trials, and if substantiated, it could establish a new treatment paradigm aimed at improving the prognosis for this high-risk patient population. Furthermore, it would provide a robust theoretical rationale and practical guidance for advancing the treatment of advanced HCC with PVTT.<\/jats:p>","DOI":"10.1136\/jitc-2025-014060","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:45:10Z","timestamp":1777293910000},"page":"e014060","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2693-1623","authenticated-orcid":false,"given":"Ying","family":"Yan","sequence":"first","affiliation":[{"name":"The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"},{"name":"Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zou","sequence":"additional","affiliation":[{"name":"The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"},{"name":"Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[{"name":"The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"},{"name":"Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Ma","sequence":"additional","affiliation":[{"name":"The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"},{"name":"Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0018-480X","authenticated-orcid":false,"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"},{"name":"Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026042705450678000_14.4.e014060.1","first-page":"1","article-title":"The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","volume":"40","author":"Qadan","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026042705450678000_14.4.e014060.2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.14701\/ahbps.2020.24.3.243","article-title":"Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies","volume":"24","author":"Kang","year":"2020","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"2026042705450678000_14.4.e014060.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1358602","article-title":"Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review","volume":"15","author":"Ai","year":"2024","journal-title":"Front Immunol"},{"key":"2026042705450678000_14.4.e014060.4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009565","article-title":"FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026042705450678000_14.4.e014060.5","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/postmj\/qgaf062","article-title":"Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study","volume":"101","author":"Niu","year":"2025","journal-title":"Postgrad Med J"},{"key":"2026042705450678000_14.4.e014060.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24890"},{"key":"2026042705450678000_14.4.e014060.7","doi-asserted-by":"publisher","DOI":"10.1148\/RADIOL.211028"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:45:12Z","timestamp":1777293912000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2025-014060"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014060","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}